Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

A 2025 study in The American Journal of Medicine found that nearly 80 percent of long‑COVID patients met the diagnostic criteria for PoTS. "Prior to the pandemic, at least 3 to 5 million people had ...

Obstructive lung diseases include asthma and chronic bronchitis, diseases that often ... According to the Yale School of Medicine, patients should consider making an appointment with a ...

By minimizing the need for invasive procedures, prolonged hospital stays, and systemic drug exposure, these approaches provide efficient and convenient solutions for managing chronic bronchitis, ...